Best Practice & Research Clinical Rheumatology
Volume 22, Issue 2 , Pages 311-323 , April 2008

Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials

References 

  1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–361
  2. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis & Rheumatism. 2000;43:2619–2633
  3. Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. Biodrugs. 2004;18:121–139
  4. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Annals of the Rheumatic Diseases. 2005;64(Suppl. 4):iv2–iv14
  5. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Seminars in Arthritis and Rheumatism. 2005;34:7–11
  6. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacology & Therapeutics. 2008;117(2):244–279
  7. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis & Rheumatism. 2003;48:2155–2162
  8. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha treatment in patients with rheumatoid arthritis. Arthritis & Rheumatism. 1996;39:1077–1081
  9. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis & Rheumatism. 2000;43:38–47
  10. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Research & Theraphy. 2004;6:R326–R334
  11. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases. 2004;63:769–773
  12. Catrina AI, Trollmo C, af Klint E, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis & Rheumatism. 2005;52:61–72
  13. Barnes T, Moots R. Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. International Journal of Nanomedicine. 2007;2:3–7
  14. Paleolog EM, Hunt M, Elliott MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis & Rheumatism. 1996;39:1082–1091
  15. Polzer K, Baeten D, Soleiman A, et al. TNF blockade increases lymphangiogenesis in murine and human arthritic joints. Annals of the Rheumatic Diseases. 3-1-2008;[epub ahead of print]
  16. Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Research & Theraphy. 2005;7:R149–R155
  17. Wijbrandts CA, Dijkgraaf MGW, Kraan MC, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pre-treatment TNF-alpha expression in the synovium. Annals of the Rheumatic Diseases. 2007; Nov 29;[epub ahead of print]
  18. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Responsiveness to anti-TNF alpha therapy is related to pre-treatment tissue inflammation levels in Rheumatoid Arthritis patients. Annals of the Rheumatic Diseases. 2007;[epub ahead of print]
  19. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis & Rheumatism. 2006;54:711–715
  20. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2007;66:921–926
  21. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. The New England Journal of Medicine. 17-6-2004;350:2572–2581
  22. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis & Rheumatism. 2006;54:1390–1400
  23. Cohen SB, Greenwald M, Totoritis MC. Efficacy and safety of rituximab in patients with active rheumatoid arthritis patients who experienced an inadequate response to one or more anti-TNF alpha therapies. Arthritis & Rheumatism. 2006;52:S677
  24. Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis & Rheumatism. 27-2-2007;56:772–778
  25. Kavanaugh A, Rosengren S, Lee SJ, et al. Assessment of rituximab's immunomodulatory synovial effects (the ARISE trial). I: clinical and synovial biomarker results. Annals of the Rheumatic Diseases. 2008;67:402–408
  26. Thurlings RM, Vos K, Wijbrandts CA, et al. Reply. Arthritis & Rheumatism; in press.
  27. Teng YK, Levarht EW, Hashemi M, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis & Rheumatism. 2007;56:3909–3918
  28. Gerlag DM, Haringman JJ, Smeets TJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis & Rheumatism. 2004;50:3783–3791
  29. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. Journal of Immunology. 2005;174:817–826
  30. Hamaguchi Y, Uchida J, Cain DW, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. Journal of Immunology. 2005;174:4389–4399
  31. Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology. 2006;154:511–517
  32. Leandro MJ, Cooper N, Cambridge G, et al. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford). 2007;46:29–36
  33. Terui Y, Sakurai T, Mishima Y, et al. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Science. 2006;97:72–79
  34. Edwards JC, Leigh RD, Cambridge G. Expression of molecules involved in B lymphocyte survival and differentiation by synovial fibroblasts. Clinical and Experimental Immunology. 1997;108:407–414
  35. Kop EN, Kwakkenbos MJ, Teske GJ, et al. Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue. Arthritis & Rheumatism. 2005;52:442–450
  36. Ruderman EM, Weinblatt ME, Thurmond LM, et al. Synovial tissue response to treatment with Campath-1H. Arthritis & Rheumatism. 1995;38:254–258
  37. Tak PP, Van der Lubbe PA, Cauli A, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis & Rheumatism. 1995;38:1457–1465
  38. Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Annals of the Rheumatic Diseases. 2007;[e-pub ahead of print]
  39. William J, Euler C, Shlomchik MJ. Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. Journal of Immunology. 2005;174:6879–6887
  40. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease?. Immunology. 1999;97:188–196
  41. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. Journal of Immunology. 2001;167:4710–4718
  42. Kaser A, Dunzendorfer S, Offner FA, et al. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. Journal of Immunology. 2000;165:2474–2480
  43. Krzysiek R, Lefevre EA, Zou W, et al. Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. Journal of Immunology. 1999;162:4455–4463
  44. Lund FE, Garvy BA, Randall TD, Harris DP. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Current Direction in Autoimmunity. 2005;8:25–54
  45. Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nature Reviews. Immunology. 2006;6:741–750
  46. Abrahams VM, Cambridge G, Lydyard PM, Edwards JC. Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis & Rheumatism. 2000;43:608–616
  47. Szekanecz Z, Szucs G, Szanto S, Koch AE. Chemokines in rheumatic diseases. Current Drug Targets. 2006;7:91–102
  48. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation?. Annals of the Rheumatic Diseases. 2004;63:1186–1194
  49. Vergunst CE, van de Sande MG, Lebre MC, Tak PP. The role of chemokines in rheumatoid arthritis and osteoarthritis. Scandinavian Journal of Rheumatology. 2005;34:415–425
  50. Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Annals of the Rheumatic Diseases. 1990;49:747–752
  51. Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annual Review of Immunology. 1994;12:775–808
  52. Wang Y, Kristan J, Hao L, et al. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. Journal of Immunology. 2000;164:4340–4347
  53. Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players. Immunity. 2002;16:157–168
  54. Vergunst CE, Gerlag DM, Dinant H, et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford). 2007;46:1773–1778
  55. Haringman JJ, Gerlag DM, Zwinderman AH, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2005;64:834–838
  56. Wijbrandts CA, Vergunst CE, Haringman JJ, et al. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis & Rheumatism. 2007;56:3869–3871
  57. Kraan MC, Patel DD, Haringman JJ, et al. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Research. 2001;3:65–71
  58. Katrib A, Tak PP, Bertouch JV, et al. Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology (Oxford). 2001;40:988–994
  59. Katschke KJ, Rottman JB, Ruth JH, et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis & Rheumatism. 2001;44:1022–1032
  60. Haringman JJ, Smeets TJ, Reinders-Blankert P, Tak PP. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Annals of the Rheumatic Diseases. 2006;65:294–300
  61. Haringman JJ, Gerlag DM, Smeets TJ, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis & Rheumatism. 2006;54:2387–2392
  62. Vergunst CE, Gerlag DM, Lopatinskaya L, et al. Modulation of CCR2 in rheumatoid arthritis. Arthritis & Rheumatism; in press.
  63. Berahovich RD, Miao Z, Wang Y, et al. Proteolytic activation of alternative CCR1 ligands in inflammation. Journal of Immunology. 2005;174:7341–7351
  64. Clucas AT, Shah A, Zhang YD, et al. Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715. Clinical Pharmacokinetics. 2007;46:757–766
  65. Gladue RP, Tylaska LA, Brissette WH, et al. CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. The Journal of Biological Chemistry. 2003;278:40473–40480
  66. Haringman JJ, Kraan MC, Smeets TJ, et al. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2003;62:715–721
  67. Gerlag D, Tak PP. Synovial biopsy. Best Practice & Research. Clinical Rheumatology. 2005;19:387–400
  68. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38:44–48
  69. Bresnihan B, Gerlag DM, Rooney T, et al. Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. The Journal of Rheumatology. 2007;34:620–622

PII: S1521-6942(08)00014-4

doi: 10.1016/j.berh.2008.02.002

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 2 , Pages 311-323 , April 2008

Article Tools

* Image Usage & Resolution